Antinuclear Antibodies Are Common and Linked to Poor Response to Omalizumab Treatment in Patients With CSU
Allergy: European Journal of Allergy and Clinical Immunology - United Kingdom
doi 10.1111/all.14033
Full Text
Open PDFAbstract
Available in full text
Date
October 3, 2019
Authors
Publisher
Wiley